Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes drugs in areas of unmet medical need such as human immunodeficiency virus (HIV) in the United States, Europe and internationally.
Revenue TTM 27.3B
Net Income TTM 6.2B
EBITDA TTM 12.5B
Debt/EBITDA TTM 2.5x
EBITDA Margin 45.9%
Net Margin 22.8%
Indeed. B Wave in a zigzag form appears to be completed. We are going down to one extent to another.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Confirmation level, where relevant, is a pink dotted, finite line....
Early Long Idea on Gilead Sciences
Gilead has navigated 2/3rds of a huge arc that has been forming since 2015, and the arc is beginning to slope vertical.
Price navigated the yellow pitchfork on the way down, and now is beginning to be directed by the purple upsloping fork.
Weekly Stoch RSI is approaching oversold levels.
I will wait for a...
I believe Gilead has made it's final low on Oct 29th. These Wyckoff accumulation patterns are very powerful reversal patterns. I will be more convinced if price breaks above the red line resistance. If that that happens, , I will start adding GILD on my portfolio. Good luck everyone
not sure about the WXY correction wave because the first zigzag is not really one (c truncated don't like it so much but bc=61,8% of ab so also not that bad)
anyway triangle in formation right now so possible trace with a low risk ratio
we would assume a wave 3 is coming
1) either enter then the triangle is broken with a stop under the e branch of the triangle